Blood Cancer Journal - Table of Contents alert Volume 2 August 2012

TABLE OF CONTENTS Volume 2, August 2012 In this issue Original Articles Letters to the Editor Sign up for e-alerts Web feed Advertisement Why Publish in Blood Cancer Journal? * High impact * Hassle-free submission * Efficient peer-review * High visibility via nature.com * Inclusion in the leading abstracting and indexing services * Submit online today. For the full Guide to Authors visit www.nature.com/bcj   Original Articles Top The novel tyrosine kinase inhibitor AKN-028 has significant antileukemic activity in cell lines and primary cultures of acute myeloid leukemia A Eriksson, M Hermanson, M Wickström, E Lindhagen, C Ekholm, A Jenmalm Jensen, A Löthgren, F Lehmann, R Larsson, V Parrow and M Höglund Blood Cancer J 2012 2: e81; 10.1038/bcj.2012.28 Abstract | Full Text Aberrant expression and biological significance of Sox2, an embryonic stem cell transcriptional factor, in ALK-positive anaplastic large cell lymphoma P Gelebart, S A Hegazy, P Wang, K M Bone, M Anand, D Sharon, M Hitt, J D Pearson, R J Ingham, Y Ma and R Lai Blood Cancer J 2012 2: e82; 10.1038/bcj.2012.27 Abstract | Full Text Epstein-Barr nuclear antigen 1 induces expression of the cellular microRNA hsa-miR-127 and impairing B-cell differentiation in EBV-infected memory B cells. New insights into the pathogenesis of Burkitt lymphoma A Onnis, M Navari, G Antonicelli, F Morettini, S Mannucci, G De Falco, E Vigorito and L Leoncini Blood Cancer J 2012 2: e84; 10.1038/bcj.2012.29 Abstract | Full Text Letters to the Editor Top Bortezomib action in multiple myeloma: microRNA-mediated synergy (and miR-27a/CDK5 driven sensitivity)? E Ballabio, M Armesto, C E Breeze, L Manterola, M Arestin, D Tramonti, C S R Hatton and C H Lawrie Blood Cancer J 2012 2: e83; 10.1038/bcj.2012.31 Full Text Molecular analysis of RAS-RAF tyrosine-kinase signaling pathway alterations in patients with plasma cell myeloma V Grossmann, U Bacher, V Artusi, A Kohlmann, N Nadarajah, W Kern, S Schnittger, T Haferlach and C Haferlach Blood Cancer J 2012 2: e85; 10.1038/bcj.2012.33 Full Text Expression of CEBPA is reduced in RUNX1-mutated acute myeloid leukemia V Grossmann, U Bacher, A Kohlmann, K Butschalowski, A Roller, S Jeromin, F Dicker, W Kern, S Schnittger, T Haferlach and C Haferlach Blood Cancer J 2012 2: e86; 10.1038/bcj.2012.34 Full Text Advertisement Blood Cancer Journal - a sister journal to the well-established and highly respected Leukemia, aiming to disseminate pre-clinical and clinical work in the field of hematology with ramifications into translational biology research down to new therapies. Editor-in-Chief: Dr Nicole Muller-Bérat Killmann Learn more about submission, advertising and the editorial team at www.nature.com/bcj   You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2012 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.